Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729579) titled 'An Open-Label, Two-Cohort, Pharmacokinetic Study in a Maximal Use Setting for Patients With Actinic Keratosis on the Upper Extremities or the Face' on July 22.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Pharmaceutical Industries Limited
Condition:
Actinic Keratosis (AK)
Intervention:
Drug: Investigational drug
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: August 4, 2026
Target Sample Size: 48
Countries of Recruitment:
United States
To know mo...